Malignant Neoplasm of the Adrenal Medulla (Malignant Pheochromocytoma)

A malignant neoplasm of the adrenal medulla is a cancer that starts in the chromaffin cells of the adrenal medulla, the inner part of the small adrenal glands that sit on top of each kidney. These cells normally make catecholamines (adrenaline/epinephrine, noradrenaline/norepinephrine, and sometimes dopamine), which help the body handle stress. When they become cancer cells, they can grow as a tumor and often release too much hormone. This causes attacks of high blood pressure, pounding heart, sweating, headaches, and anxiety. The tumor is called malignant when it spreads (metastasizes) to places where chromaffin cells do not normally live, such as lymph nodes, bone, liver, or lungs. Malignancy is not judged only by how the tumor looks under a microscope; it is defined by metastasis. Many cases are linked to inherited gene changes. Treatment needs careful planning because hormones from the tumor can make surgery and anesthesia risky without proper control.

---

Another names

This disease is also called malignant pheochromocytoma, adrenal medullary carcinoma (chromaffin cell type), malignant chromaffinoma (older term), catecholamine-secreting adrenal tumor, and malignant adrenal pheochromocytoma. When a similar cancer starts outside the adrenal gland in nerve-related tissue, it is called malignant paraganglioma; together they are often grouped as PPGL (pheochromocytoma and paraganglioma). Some reports use neuroendocrine tumor of the adrenal medulla or adrenergic neuroendocrine carcinoma. A few tumors mainly make dopamine and are called dopaminergic pheochromocytomas. The word “malignant” here means the tumor has spread to distant sites or invaded nearby structures; it does not simply mean “looks aggressive” under the microscope.

---

Types

By location:

• Adrenal medulla (classic pheochromocytoma) on one or both sides.

• Extra-adrenal (paraganglioma) when similar tumors start in sympathetic nerve tissue outside the adrenals; some of these can still be linked to adrenal disease patterns.

By behavior:

• Non-metastatic (no spread detected yet) but with features suggesting higher risk.

• Malignant (proven metastasis to lymph nodes, bone, liver, lungs, or other sites).

By biochemical pattern:

• Adrenergic (mainly epinephrine/metanephrine).

• Noradrenergic (mainly norepinephrine/normetanephrine).

• Dopaminergic (dopamine/3-methoxytyramine), less common but often more aggressive.

By genetics (very simplified):

• Pseudohypoxia cluster (for example VHL, SDHx, EPAS1/HIF-2α): often noradrenergic and higher metastatic risk with some SDHB variants.

• Kinase-signaling cluster (for example RET/MEN2, NF1, TMEM127, MAX, HRAS): frequently adrenergic.

• Wnt-altered cluster (rarer rearrangements): variable behavior.

By clinical setting:

• Sporadic (no family history).

• Hereditary/syndromic (MEN2, VHL, NF1, SDHx, and others).

---

Causes

1. RET gene mutations (MEN2A/MEN2B). A change in the RET gene activates cell-growth signals. People with MEN2 can develop adrenal medulla tumors that often secrete epinephrine. Inherited in families (autosomal dominant).

2. VHL gene mutations (Von Hippel–Lindau syndrome). Faulty VHL protein stabilizes hypoxia pathways, driving tumor growth. Tumors are often noradrenergic and may be multiple.

3. NF1 gene mutations (Neurofibromatosis type 1). Loss of neurofibromin increases RAS signaling, raising the chance of adrenal medulla tumors along with café-au-lait spots and neurofibromas.

4. SDHB mutations. Loss of this mitochondrial complex II subunit shifts metabolism and increases reactive oxygen signals. SDHB-related tumors have a higher metastatic risk.

5. SDHD mutations. Also part of succinate dehydrogenase. Tumor risk is high, especially for head-and-neck paragangliomas, and inheritance shows a parent-of-origin effect.

6. SDHC mutations. Less common but similar metabolic effects that promote tumor growth.

7. SDHA and SDHAF2 mutations. Disrupt the same enzyme system, causing “pseudohypoxia” and tumor formation.

8. TMEM127 mutations. Alter mTOR pathway control and cell growth signals, predisposing to adrenal medulla tumors.

9. MAX mutations. Affect a key partner of MYC; loss changes cell-cycle control and supports tumor formation, sometimes bilaterally.

10. EPAS1 (HIF-2α) mutations. Turn on hypoxia-responsive genes even in normal oxygen, promoting vessel growth and tumor survival.

11. EGLN1/PHD2 mutations. Reduce breakdown of HIF proteins, again mimicking hypoxia and driving tumor growth.

12. KIF1Bβ mutations. Interfere with programmed cell death (apoptosis) in neural crest cells, allowing abnormal cells to persist.

13. FH (fumarate hydratase) mutations. Disrupt the Krebs cycle, leading to metabolite buildup and oncogenic signals.

14. HRAS somatic mutations. Not inherited but acquired in the tumor; push strong growth signaling.

15. ATRX alterations. Affect chromatin remodeling and telomere maintenance, associated with aggressive behavior in some tumors.

16. MDH2 mutations. Another metabolic enzyme change linked to tumor susceptibility.

17. Family history of pheochromocytoma/paraganglioma. Even without a known gene, clustered cases increase risk.

18. Chronic hypoxia (for example, cyanotic heart disease or long-term life at very high altitude). Long-term low oxygen can pressurize the same hypoxia pathways.

19. Prior radiation exposure to the abdomen (rare link). Radiation may damage DNA in adrenal medulla cells.

20. Sporadic somatic mutations with age. Random DNA errors that accumulate over time can start tumor growth even without a known inherited syndrome.

---

Symptoms

1. Paroxysmal high blood pressure. Sudden spikes with pounding in the head or chest. Between attacks the pressure may be normal or constantly high.

2. Severe headache. Throbbing pain, often with palpitations and sweating, due to catecholamine surges.

3. Palpitations and rapid heartbeat. The heart races or skips, sometimes with chest tightness.

4. Profuse sweating. Sudden drenching sweats during spells, often with pale or clammy skin.

5. Anxiety or panic attacks. A feeling of dread, shaking, and restlessness triggered by hormone bursts.

6. Tremor. Hands shake because adrenaline stimulates the nervous system.

7. Pallor or flushing. Fast shift in skin blood flow can cause sudden paleness (more typical) or, less often, flushing.

8. Shortness of breath. Fast heart rate and high blood pressure can make breathing feel difficult.

9. Chest pain. Strain on the heart may cause angina-like pain; this needs urgent assessment.

10. Nausea or vomiting. Stress hormones slow the gut and can cause stomach upset.

11. Abdominal or flank pain. From tumor mass effect or rapid blood pressure changes.

12. Weight loss. High catecholamines raise metabolic rate and reduce appetite.

13. Heat intolerance. The body feels overheated during hormone surges.

14. High blood sugar with thirst and urination. Adrenaline raises glucose, so some people get hyperglycemia episodes.

15. Dizziness or fainting on standing. Paradoxically, big surges may cause orthostatic hypotension between attacks due to volume depletion and receptor down-regulation.

---

Diagnostic tests

Physical exam

1) Repeated blood-pressure measurement in clinic.
The doctor measures blood pressure several times, ideally in both arms, and at different visits. Sudden spikes or very high numbers suggest catecholamine excess. Normal readings do not rule out disease because attacks can be episodic.

2) Orthostatic vital signs (lying-to-standing test).
Blood pressure and pulse are checked while lying down and again after standing. A fall in pressure with a rise in pulse can occur between catecholamine surges. Marked variability supports a hormone-driven cause.

3) Heart and pulse examination.
The examiner looks for a very fast or irregular pulse, new murmurs, or signs of heart strain that can follow long periods of uncontrolled high blood pressure.

4) Eye (fundus) examination.
Using an ophthalmoscope, the clinician looks for hypertensive retinopathy—narrowed arteries, hemorrhages, or swelling—showing damage from repeated pressure spikes.

Manual / bedside assessments

5) Home blood-pressure log.
The person measures blood pressure at home, especially during headaches, palpitations, or sweating spells. A diary of spikes helps connect symptoms to pressure surges and guides timing of lab tests.

6) Symptom and trigger diary.
Writing down when attacks happen and what occurred just before them (for example, intense exercise, emotional stress, surgery, certain drugs, or tyramine-rich foods) helps identify catecholamine-linked patterns. It is non-invasive and safe.

7) Capillary glucose check during an episode.
A simple finger-stick glucose during a spell can show high sugar due to adrenaline. This does not diagnose the tumor but supports the hormonal effect and alerts providers to glucose control needs.

Laboratory and pathological tests

8) Plasma free metanephrines.
This is a first-line blood test. Metanephrines are breakdown products of catecholamines made continuously inside tumor cells. High values, especially when greatly above the upper limit, strongly suggest pheochromocytoma. Blood is ideally drawn after 20–30 minutes of quiet rest, lying down.

9) 24-hour urinary fractionated metanephrines and catecholamines.
Urine is collected for a full day to measure hormone metabolites over time. It is useful when attacks are episodic or when blood results are borderline. Very high results support the diagnosis.

10) Plasma catecholamines (epinephrine, norepinephrine, dopamine).
Less sensitive than metanephrines because hormones fluctuate, but very high levels during symptoms can be diagnostic. This test is affected by stress, posture, and many medicines.

11) Plasma 3-methoxytyramine.
This tests for extra dopamine production. Elevated levels can point to tumors with a dopaminergic pattern, which can be more aggressive and linked to certain genes.

12) Chromogranin A.
A general neuroendocrine tumor marker that is often elevated. It is not specific and can be high for other reasons (for example, proton pump inhibitors), but it can help follow tumor burden over time.

13) Clonidine suppression test (specialized).
Clonidine lowers sympathetic nerve release. In many patients with true tumor secretion, plasma normetanephrine does not fall after clonidine, helping separate tumor production from stress-related elevation. This test is done only in controlled settings and after expert review.

14) Genetic testing panel.
Testing for RET, VHL, NF1, SDHx (A, B, C, D, AF2), TMEM127, MAX, EPAS1/HIF-2α, EGLN1/PHD2, FH, and others can find a hereditary cause. A result changes screening for the patient and family and can guide which imaging tracer is best.

15) Tumor histology and immunohistochemistry (after surgery or biopsy of a metastasis).
Under the microscope, cells show the classic “zellballen” nesting pattern. Stains are positive for chromogranin A and synaptophysin in tumor cells, and S100/SOX10 highlights sustentacular cells. SDHB immunostain loss suggests an SDH mutation. Scores such as PASS and GAPP and markers like Ki-67 help estimate risk, but metastasis defines malignancy.

Electrodiagnostic and cardiovascular testing

16) 12-lead electrocardiogram (ECG).
Adrenaline surges can cause sinus tachycardia, arrhythmias, or ischemia-like changes. An ECG provides a quick look at rhythm problems and baseline status before treatment.

17) 24-hour Holter or event monitor.
Continuous heart-rhythm recording can capture episodes of rapid heartbeat, atrial fibrillation, or other arrhythmias that correlate with symptoms and blood-pressure spikes.

Imaging tests

18) Adrenal-protocol CT scan.
CT provides high-resolution images of the adrenal glands and nearby structures. Pheochromocytomas often appear as well-defined adrenal masses with strong enhancement. CT also checks for spread to lymph nodes, liver, or lungs.

19) MRI of the adrenals and abdomen.
MRI avoids radiation and is useful in younger people and pregnancy. Many pheochromocytomas look very bright on T2-weighted images. MRI is excellent for seeing invasion into vessels and spine and for evaluating liver and bone marrow.

20) Functional imaging (one chosen based on case and gene).

• 123I-MIBG scintigraphy looks for norepinephrine transporter–positive tumor tissue and can guide MIBG therapy when available.

• 68Ga-DOTATATE PET/CT targets somatostatin receptors and is strong for many hereditary cases (for example, SDHx).

• 18F-FDG PET/CT shows high-glucose uptake and is useful for aggressive or SDHB-related disease.

• 18F-DOPA or 18F-fluorodopamine PET (where available) can be very sensitive for catecholamine-producing tissue. The choice depends on availability, biochemical pattern, and genetics.

Non-pharmacological treatments

Physiotherapy

1. Pre-op walking program: Gentle daily walks build aerobic reserve before surgery, lowering surgical risk and improving recovery. Mechanism: enhances endothelial function and autonomic balance. Benefit: better BP control and fitness.

2. Breathing training (diaphragmatic): Slow nasal breathing reduces sympathetic outflow. Purpose: fewer spikes. Mechanism: vagal activation. Benefit: calmer pulse and BP.

3. Isometric handgrip—avoided before alpha-blockade: After BP is controlled, brief, supervised isometrics improve baroreflex. Mechanism: trains vascular response. Benefit: steadier BP.

4. Post-op early mobilization: Out-of-bed on day 0–1 reduces clots and pneumonia. Mechanism: venous return and lung expansion. Benefit: faster discharge.

5. Core strengthening: Gentle core work protects posture after flank or midline incision. Mechanism: stabilizes trunk. Benefit: less pain, quicker function.

6. Balance and gait drills: Prevents falls after BP medications cause orthostatic symptoms. Mechanism: neuromuscular adaptation. Benefit: safer mobility.

7. Flexibility/stretching: Hip and back stretches ease incision-related tightness. Mechanism: reduces myofascial tension. Benefit: better range and comfort.

8. Pelvic and diaphragmatic synergy: Coordinating breath with gentle abdominal activation supports lymph flow. Benefit: less post-op bloating.

9. Light resistance bands (supervised): Builds strength without big BP spikes once cleared. Benefit: stamina for daily tasks.

10. Stationary cycling (low intensity): Safe aerobic option with continuous monitoring. Mechanism: improves VO₂. Benefit: energy and mood.

11. Incentive spirometry: Prevents atelectasis after anesthesia. Benefit: fewer lung issues.

12. Scar mobility and posture re-education: Gentle massage and posture cues reduce pain and adhesions. Benefit: comfort and function.

13. Edema management: Elevation, ankle pumps, and compression if advised. Benefit: decreases swelling.

14. Return-to-work conditioning: Task-specific drills restore lifting, reaching, or desk endurance. Benefit: smoother reintegration.

15. Bone health exercises (metastatic disease): Low-impact loading plus fall-prevention protects fragile bone. Benefit: fracture risk reduction.

Mind-Body / “Gene-informed” self-care

16. Guided relaxation: 10–15 minutes daily reduces stress-triggered catecholamine surges. Mechanism: parasympathetic activation.

17. Mindfulness for pain and anxiety: Trains non-reactivity to symptom spikes. Mechanism: cortical control over limbic arousal.

18. Cognitive-behavioral sleep hygiene: Better sleep lowers sympathetic tone. Mechanism: stabilizes circadian cortisol/catecholamines.

19. Trigger audit and substitution: Identify stimulants (caffeine, decongestants) and replace with safe options. Mechanism: reduces provocation.

20. Family genetic counseling participation: Not a drug, but a behavioral action that reduces uncertainty and supports screening of at-risk relatives.

Educational therapy

21. Medication literacy coaching: How to take alpha-blockers/beta-blockers correctly; why hydration and salt matter pre-op.

22. Home BP/HR skills: Teach accurate cuff use, log keeping, and red-flag thresholds.

23. Sick-day rules: What to do with vomiting, dehydration, or fever to avoid crashes.

24. Procedure prep modules: What to expect for MIBG or PRRT days; radiation safety at home.

25. Survivorship plan: Clear schedule for labs, imaging, bones, and heart checks; lifestyle goals.

Drug treatments

(Typical classes, common doses/schedules; clinicians individualize. Side effects are common examples.)

1. Phenoxybenzamine (non-selective α-blocker): Class: irreversible α-adrenergic blocker. Dose: start 10 mg twice daily, titrate every 2–3 days to BP/HR and symptom control. Purpose: prevent dangerous BP spikes pre-op. Mechanism: blocks vasoconstriction from catecholamines. Side effects: nasal stuffiness, fatigue, orthostatic dizziness.

2. Doxazosin / Prazosin (selective α1-blockers): Doxazosin 1 mg nightly and titrate; prazosin 1 mg 2–3×/day. Purpose: alternative or add-on to phenoxybenzamine. Mechanism: α1 blockade lowers vascular tone. Side effects: lightheadedness, edema.

3. Propranolol / Metoprolol (β-blockers, only after α-blockade): Propranolol 10–40 mg 3×/day; metoprolol 25–50 mg 1–2×/day. Purpose: control tachycardia/arrhythmia. Mechanism: β-receptor blockade. Side effects: fatigue, bronchospasm in asthma.

4. Metyrosine: Class: catecholamine synthesis inhibitor. Dose: 250 mg 3–4×/day, titrate up to 1–4 g/day. Purpose: lower hormone production when secretion is heavy. Side effects: sedation, depression, extrapyramidal symptoms (rare).

5. Nicardipine / Nitroprusside (IV crisis control): Used in ICU for severe spikes. Mechanism: arterial vasodilation (nicardipine), nitric oxide donor (nitroprusside). Side effects: hypotension; with nitroprusside, thiocyanate risk if prolonged.

6. Cyclophosphamide + Vincristine + Dacarbazine (CVD chemo): Cycle every 21–28 days (e.g., cyclophosphamide 750 mg/m² day 1, vincristine 1.4 mg/m² day 1, dacarbazine 600–750 mg/m² days 1–2). Purpose: shrink metastatic disease. Side effects: nausea, low blood counts, neuropathy.

7. Temozolomide ± Capecitabine: Temozolomide 150–200 mg/m² days 1–5 q28d. Useful especially in SDHB tumors. Mechanism: DNA alkylation; capecitabine enhances effect in some protocols. Side effects: fatigue, cytopenias.

8. Sunitinib (TKI): 37.5–50 mg daily (continuous or 4/2 schedule). Purpose: target VEGF pathways, slow growth. Side effects: hand-foot syndrome, hypertension, mucositis.

9. Pazopanib / Lenvatinib / Cabozantinib (TKIs): Typical daily oral dosing (pazopanib 800 mg; lenvatinib often 14–24 mg; cabozantinib 60 mg). Purpose: anti-angiogenic/kinase blockade. Side effects: fatigue, diarrhea, BP rise, proteinuria.

10. Octreotide LAR / Lanreotide: LAR 20–30 mg IM q4 weeks; lanreotide 120 mg q4 weeks. Purpose: symptom control and stabilization in somatostatin-receptor-positive disease. Side effects: gallstones, GI upset.

11. 177-Lu DOTATATE (PRRT): Radioligand given IV every 8 weeks ×4 in specialized centers. Purpose: delivers targeted radiation to receptor-positive tumors. Side effects: nausea, transient marrow suppression.

12. 131-I MIBG therapy: High-specific-activity regimens in selected MIBG-avid tumors. Purpose: radiotherapeutic targeting. Side effects: marrow suppression, need for radiation precautions.

13. External-beam radiotherapy / SBRT (as a “drug-like” local therapy): For bone or soft-tissue metastases to reduce pain and control growth. Side effects: local skin/organ effects depending on site.

14. Bisphosphonates (Zoledronic acid) or Denosumab: Zoledronic acid 4 mg IV q4 weeks; denosumab 120 mg SC q4 weeks. Purpose: protect bone, reduce skeletal events. Side effects: low calcium, rare osteonecrosis of jaw.

15. Pembrolizumab (Immunotherapy, selected cases): Dosing per protocol (e.g., 200 mg IV q3 weeks). Purpose: unleashes immune attack in refractory disease; evidence is emerging. Side effects: immune-related (thyroiditis, colitis, hepatitis).

Dietary molecular supplements

(Supportive only—not a cure. Discuss with the oncology/endocrine team.)

1. Vitamin D3: 1000–2000 IU/day (adjust to levels). Function: bone and immune support, important with bone mets or antiresorptives. Mechanism: nuclear receptor signaling in bone/immune cells.

2. Calcium citrate: 500–600 mg elemental Ca/day if intake is low, especially with denosumab/zoledronic acid. Function: bone mineral support. Mechanism: provides substrate for bone turnover.

3. Omega-3 (EPA/DHA): 1–2 g/day. Function: anti-inflammatory, may help cardiovascular health. Mechanism: membrane lipid signaling.

4. Magnesium (as needed): 200–400 mg/day. Function: supports rhythm and muscle function; some drugs disturb Mg.

5. B-complex (esp. B12, folate): As per deficiency. Function: hematologic and nerve support during chemo.

6. Protein supplement (whey/plant): 20–30 g/day if intake low. Function: preserves lean mass during treatment. Mechanism: mTOR-mediated muscle protein synthesis.

7. Probiotic (lactobacillus/bifido): Daily. Function: GI tolerance on TKIs/chemo (diarrhea). Mechanism: microbiome modulation.

8. CoQ10 (caution): 100–200 mg/day. Function: mitochondrial support; discuss given theoretical interactions.

9. Fiber (psyllium): 5–10 g/day. Function: bowel regularity with opioids or antiemetics.

10. Electrolyte solution (oral rehydration): As needed around therapy days. Function: stable BP/HR and kidney safety.

Immunity booster / regenerative / stem-cell–related” therapies

(Supportive or investigational; none are stand-alone cures.)

1. Seasonal vaccines (influenza, COVID-19, others per guideline): Dose per schedule. Function: prevent treatment interruptions from infections. Mechanism: adaptive immune priming.

2. Exercise-induced immunomodulation: Dose: 150 minutes/week moderate activity as tolerated. Function: improves NK cell activity and lowers inflammation.

3. Adequate protein (1.0–1.2 g/kg/day): Function: supports immune cells and wound healing.

4. Hematopoietic growth factors (e.g., G-CSF) when indicated: Dose per ANC and chemo plan. Function: reduce neutropenia risk.

5. Bone-targeted remodeling (denosumab/zoledronic) as “regenerative” bone support: Protects micro-architecture, lowers fracture risk.

6. Clinical trials of cell or radioligand therapies: Function: access to cutting-edge regenerative/targeted approaches (e.g., novel PRRT, CAR-NK in trials). Mechanism: harnesses or augments host immunity.

Surgeries

1. Laparoscopic adrenalectomy (unilateral): Minimally invasive removal of the cancerous adrenal. Why: cure or debulk localized disease; fewer complications, faster recovery.

2. Open adrenalectomy with en-bloc resection: For large, invasive, or adherent tumors. Why: achieve safe margins and control local invasion.

3. Cortical-sparing adrenalectomy (selected hereditary bilateral disease): Removes tumor while preserving some cortex. Why: reduce lifelong steroid dependence.

4. Lymph node dissection: Removes involved nodes. Why: staging and local control when nodes are positive.

5. Metastasectomy or ablative procedures (liver RFA, microwave, embolization): For limited metastases. Why: symptom relief and disease control.

Preventions

1. Genetic counseling and testing in families with pheo/paraganglioma.

2. Regular screening (metanephrines and imaging as indicated) for mutation carriers.

3. Avoid provoking drugs (unopposed sympathomimetics, MAOIs without supervision, cocaine).

4. Caffeine and energy drink restraint to reduce triggers.

5. Careful decongestant choice (avoid pseudoephedrine/phenylephrine unless cleared).

6. Pre-op alpha-blockade + hydration + salt to prevent crises during surgery.

7. Home BP monitoring with a plan for spikes.

8. Treat sleep apnea to lower sympathetic overload.

9. Heart-healthy lifestyle (exercise, weight, salt targets guided by team).

10. Follow-up schedule adherence to catch recurrence early.

When to see doctors (red flags)

• Sudden severe headache, chest pain, shortness of breath, or very high BP—seek emergency care.

• New pounding heartbeat, fainting, or seizures.

• Uncontrolled vomiting, dehydration, or fever during treatment.

• New bone pain, weight loss, or neurologic symptoms suggesting spread.

• Any BP spike in pregnancy or in someone with a known syndrome (MEN2, VHL, NF1, SDHx).

• Medication side effects such as severe dizziness, black stools, or jaundice.

What to eat and what to avoid

• Eat: Balanced meals with adequate salt and fluids pre-op (as directed during alpha-blockade), lean proteins, whole grains, fruits/vegetables, calcium and vitamin D sources, and fiber for bowel health.

• Avoid or limit: Caffeine, energy drinks, alcohol binges, and decongestant-containing “energy shots.”

• Avoid unapproved herbal stimulants (yohimbine, synephrine, high-dose ginseng/guarana).

• If on MAOIs for other reasons, strictly avoid tyramine-rich foods (aged cheeses, cured meats) to prevent hypertensive crises.

• With TKIs, avoid grapefruit products (CYP3A4 interactions).

• If diarrhea from therapy, choose BRAT-style foods and oral rehydration; if constipation, add fiber and fluids.

• Consistent carbohydrate intake if on steroids or with stress hyperglycemia.

• Small, frequent meals around treatment days to steady BP and glucose.

• Food safety measures if neutropenic (wash produce, avoid raw seafood).

• Discuss supplements with your team to prevent drug interactions.

FAQs

1. Is every adrenal medulla tumor cancer? No. Many are benign, but some are malignant by invasion or spread.

2. What makes it dangerous? Surges of catecholamines can cause stroke, heart attack, or crisis, and the tumor can spread.

3. Can blood pressure be normal? Yes—some patients have normal readings between spells.

4. Why alpha-blockers first? Blocking α-receptors prevents dangerous vasoconstriction; β-blockers alone can worsen BP.

5. Is surgery always needed? Usually yes for localized disease; it is the main curative option.

6. Will I need both adrenals removed? Only if bilateral disease; doctors try to spare cortex when safe.

7. What if cancer has spread? Options include TKIs, chemotherapy, PRRT, MIBG therapy, and focused radiation.

8. Do genes matter? Yes—up to half have a hereditary cause; testing shapes care and family screening.

9. How often is follow-up? Typically every 3–12 months with labs and imaging depending on risk.

10. Can I exercise? Yes, once cleared and BP is controlled; start light and build gradually.

11. Can stress cause attacks? Stress can trigger symptoms; relaxation skills help, but the tumor is the source.

12. Are supplements enough? No. They are supportive only and do not treat the cancer.

13. What about pregnancy? Needs a high-risk team; timing of surgery and blockers is carefully planned.

14. Will I make normal hormones after surgery? If one adrenal remains and is healthy, usually yes; if both are removed, you’ll need steroid replacement.

15. What is the outlook? Many do well with timely surgery and modern therapies; prognosis varies by genetics, spread, and response to treatment.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 09, 2025.